NCT05021640View on ClinicalTrials.gov

Study of DCR-AUD in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Alcohol Use Disorder (AUD)
Interventions
DRUG

DCR-AUD

DCR-A1203, the drug substance of DCR-AUD, is a synthetic double-stranded (hybridized duplex) RNA oligonucleotide conjugated to GalNAc ligands that enable specific hepatic access and uptake after subcutaneous administration. DCR-AUD is a sterile solution of DCR-A1203 at a concentration of 160 mg/mL in water for injection (WFI).

DRUG

Placebo for DCR-AUD

0.9% saline for injection

Trial Locations (1)

91206

Parexel Los Angeles Early Phase Clinical Unit, Glendale

All Listed Sponsors
lead

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY

NCT05021640 - Study of DCR-AUD in Healthy Volunteers | Biotech Hunter | Biotech Hunter